An ongoing phase I trial (NCT00902044; active, not recruiting) is designed to evaluate the safety of autologous HER2 CAR T cells after lymphodepletion in patients with advanced sarcoma and incorporates multiple CAR T-cell infusions to improve their persistence. This evidence concerns the gene ERBB2 and sarcoma.